Literature DB >> 19184311

Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy.

Phil Young Lee1, Ki Seok Kim2, Won Ki Lee3,4.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) has proven beneficial in the treatment of central serous chorioretinopathy (CSC). CASES: Two patients with serous pigment epithelial detachments (PEDs) and one patient with chronic CSC developed an abrupt visual loss caused by severe choroidal ischemia following PDT. Serous PEDs in the two patients were regarded as a latent variant of CSC. PDT was performed in accordance with the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy guidelines. OBSERVATIONS: Although following PDT, PEDs and serous sensory retinal detachments resolved in all patients, the laser-treated areas of the patients revealed severe choroidal ischemia and their visual acuity decreased. Only in case 1 did visual acuity recover to the pretreatment level 2 months after treatment. In case 2, visual acuity was still reduced 7 months after treatment. In case 3, secondary choroidal neovascularization developed in the treatment area 1 month after treatment.
CONCLUSIONS: In the CSC variant associated with PED only or in chronic CSC, PDT performed by the standard procedure can increase the risk of severe choroidal ischemia. Further studies are needed to find safe and optimal PDT parameters.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184311     DOI: 10.1007/s10384-008-0613-z

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  5 in total

1.  Choroidal findings in the course of idiopathic serous pigment epithelium detachment detected by indocyanine green videoangiography.

Authors:  A Giovannini; B Scassellati-Sforzolini; E D'Altobrando; C Mariotti; T Rutili; R Tittarelli
Journal:  Retina       Date:  1997       Impact factor: 4.256

2.  Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.

Authors:  T Y Y Lai; W-M Chan; H Li; R Y K Lai; D T L Liu; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-04-05       Impact factor: 4.638

3.  Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy.

Authors:  T Iida; S Kishi; N Hagimura; K Shimizu
Journal:  Retina       Date:  1999       Impact factor: 4.256

4.  Photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Felice Cardillo Piccolino; Chiara M Eandi; Luca Ventre; Roberta C Rigault de la Longrais; Federico M Grignolo
Journal:  Retina       Date:  2003-12       Impact factor: 4.256

5.  Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study.

Authors:  Lawrence A Yannuzzi; Jason S Slakter; Nicole E Gross; Richard F Spaide; Danielle L L Costa; Sheau J Huang; James M Klancnik; Alexander Aizman
Journal:  Retina       Date:  2003-06       Impact factor: 4.256

  5 in total
  31 in total

1.  Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy.

Authors:  M J Koss; I Beger; F H Koch
Journal:  Eye (Lond)       Date:  2011-11-11       Impact factor: 3.775

2.  Combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy.

Authors:  J Fernando Arevalo; Juan V Espinoza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-06       Impact factor: 3.117

3.  A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

Authors:  Colin S Tan; Kai Xiong Cheong; Louis W Lim; Shoun Tan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-09       Impact factor: 3.117

4.  Half-dose photodynamic therapy for chronic central serous chorioretinopathy evaluated by focal macular electroretinograms.

Authors:  Kazuhiro Oiwa; Keiko Kataoka; Ruka Maruko; Shinji Ueno; Yasuki Ito; Hiroko Terasaki
Journal:  Jpn J Ophthalmol       Date:  2017-02-02       Impact factor: 2.447

5.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

6.  Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Chun-Fu Liu; Lee-Jen Chen; Shawn H Tsai; Chi-Chun Lai; Wei-Chun Chan; Wei-Chi Wu; Nan-Kai Wang; Kuan-Jen Chen; Yih-Shiou Hwang; Yen-Po Chen; Ling Yeung
Journal:  J Ocul Pharmacol Ther       Date:  2014-03-05       Impact factor: 2.671

7.  Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.

Authors:  J Fernando Arevalo; Juan V Espinoza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-30       Impact factor: 3.117

8.  [Treatment of central serous chorioretinopathy: MicroPulse photocoagulation versus bevacizumab].

Authors:  I Beger; M J Koss; F Koch
Journal:  Ophthalmologe       Date:  2012-12       Impact factor: 1.059

9.  Chorioretinal response to intravitreal aflibercept injection in acute central serous chorioretinopathy.

Authors:  Byung Ju Jung; Kook Lee; Jin Hyung Park; Jae Hyung Lee
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

Review 10.  Photodynamic therapy for central serous chorioretinopathy.

Authors:  O C Erikitola; R Crosby-Nwaobi; A J Lotery; S Sivaprasad
Journal:  Eye (Lond)       Date:  2014-06-20       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.